Interview with Arial Therapeutics CEO Bill Stilley

Bill Stilley was a Navy brat who somehow ended up in the Marine Corps. After his service there he shifted into business and finance across various industries, and eventually found his way to life sciences.

As CEO of Adial Pharmaceuticals, he’s leading the development of a genetically targeted therapeutic agent for alcohol use disorder. Adial is currently completing a Phase III trial to determine whether this oral medication can reduce overall alcohol use and the number of heavy drinking days. If that works, Adial has products in the pipeline for other addictions, and a broader set of programs starting with asthma and pain.

When he’s not hard at work at Adial, Bill is reading about Genghis Khan and about negotiation strategy.

The HealthBiz podcast is available on Spotify, Apple Podcasts, Google Podcasts, YouTube and  many more services.

By healthcare business consultant David E. Williams, president of Health Business Group.